Annovis Bio, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ANVS New York 2830 www.annovisbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Annovis Bio, Inc.

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE - Mar 27th, 2025 8:30 pm
Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program - Mar 25th, 2025 12:00 pm
Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results - Mar 21st, 2025 9:05 pm
Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment - Mar 11th, 2025 12:00 pm
Annovis to Host Patients’ Live Forum on February 27, 2025 - Feb 19th, 2025 1:30 pm
Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference - Feb 7th, 2025 1:00 pm
Annovis begins treatment of subjects in Alzheimer’s trial - Feb 6th, 2025 4:21 pm
Annovis Bio announces first patients entered Phase 3 study of buntanetap - Feb 6th, 2025 1:20 pm
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease - Feb 5th, 2025 1:00 pm
Annovis Bio, Inc. Announces Closing of $21 Million Public Offering - Feb 4th, 2025 9:31 pm
Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering - Feb 3rd, 2025 11:22 am
Annovis Bio, Inc. Announces Proposed Public Offering - Feb 1st, 2025 1:14 am
Annovis Bio granted U.S. patent covering buntanetap - Jan 15th, 2025 1:11 pm
Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection - Jan 14th, 2025 1:00 pm
FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway - Jan 7th, 2025 1:00 pm
Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s Marketplace - Dec 5th, 2024 1:30 pm
Annovis to Host Year-End Investor Webcast on December 11, 2024 - Nov 25th, 2024 1:00 pm
Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB) - Nov 12th, 2024 1:00 pm
Annovis Bio Reports Third Quarter Financial Results and Provides Business Update - Nov 11th, 2024 1:00 pm
Will Annovis Bio (NYSE:ANVS) Spend Its Cash Wisely? - Nov 11th, 2024 11:20 am